| Outcome Measures: |
Primary: The Percent Change in Proteinuria, % change in proteinuria from baseline (timepoint week 0) through timepoint week 24, which was 12 weeks after completion of Harvoni., Baseline and 24 weeks (12 weeks after completion of Harvoni) | Secondary: Median Change in eGFR From Baseline to Timepoint Week 24, Median change from baseline (timepoint week 0) to timepoint week 24, which was 12 weeks after completion of Harvoni. Median change in eGFR was calculated using the creatinine and cystatin C-based estimating equation. eGFR = 135 × min(SCr/κ, 1)α × max(SCr/κ, 1)-0.601 × min(Scys/0.8, 1)-0.375 × max(Scys/0.8, 1)-0.711 × 0.995Age × 0.969 \[if female\] × 1.08 \[if black\], 24 weeks|Number of Participants With ≥25% Reduction in Proteinuria, Number of participants with at least -25% change in proteinuria, calculated from baseline (timepoint week 0) to timepoint week 24, which is 12 weeks after completion of Harvoni., 24 weeks|Mean Time in Weeks to Maximum Reduction in Proteinuria, This outcome evaluated all post-baseline proteinuria values through the 52 week followup, and determined which demonstrated the greatest negative change (reduction) from baseline. We then calculate the mean time to maximum reduction of proteinuria., 52 weeks|Median Change in eGFR From Baseline to Timepoint Week 52, Median change from baseline (timepoint week 0) to timepoint week 52, which was 40 weeks after completion of Harvoni. Median change in eGFR was calculated using the creatinine and cystatin C-based estimating equation. eGFR = 135 × min(SCr/κ, 1)α × max(SCr/κ, 1)-0.601 × min(Scys/0.8, 1)-0.375 × max(Scys/0.8, 1)-0.711 × 0.995Age × 0.969 \[if female\] × 1.08 \[if black\], 52 weeks|Change in Urinary β-2microglobulin Levels Before Therapy, Change in urinary β-2microglobulin levels before therapy with ledipasvir/sofosbuvir fixed dose combination pill. β-2microglobulin (mcg/L) change prior to initiating HCV-treatment. This outcome was not assessed., 24 weeks|Change in Urinary β-2microglobulin Levels After Therapy, Change in urinary β-2microglobulin levels after therapy with ledipasvir/sofosbuvir fixed dose combination pill β-2microglobulin (mcg/L) levels were assessed at baseline (timepoint week 0) and at timepoint week 24. Change was recorded for each patient, and presented as a median with IQR., 24 weeks
|
